Targeted antibodies against CD123 currently tested in AML include, among others, the CD123/CD3 DART flotetuzumab, the CD123/CD3-engaging IgG4 DuoBody JNJ-63709178, and the CD123-targeting X-mAb XmAb14045 (Table 3) [140,141,142]. This evidence concerns the gene IL3RA and acute myeloid leukemia.